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OBJECTIVES This study was designed to compare the hemodynamic efficacy of nonsurgical septal reduction
therapy (NSRT) by intracoronary ethanol with standard therapy (surgical myectomy) for the
treatment of hypertrophic obstructive cardiomyopathy (HOCM).
BACKGROUND Nonsurgical septal reduction therapy has gained interest as a new treatment modality for
patients with drug-refractory symptoms of HOCM; however, its benefits in comparison to
surgery are unknown.
METHODS Forty-one consecutive NSRT patients at Baylor College of Medicine with one-year follow-up
were compared with age- and gradient-matched septal myectomy patients at the Mayo
Clinic. All patients had left ventricular outflow obstruction with a resting gradient
40 mm Hg and none had concomitant procedures.
RESULTS There were no baseline differences in New York Heart Association class, severity of mitral
regurgitation, use of cardiac medications or exercise capacity. One death occurred during
NSRT because of dissection of the left anterior descending artery. At one year, all
improvements in both groups were similar. After surgical myectomy, more patients were on
medications (p  0.05) and there was a higher incidence of mild aortic regurgitation (p 
0.05). After NSRT, the incidence of pacemaker implantation for complete heart block was
higher (22% vs. 2% in surgery; p  0.02). However, seven of the nine pacemakers in the
NSRT group were implanted before a modified ethanol injection technique and the use of
contrast echocardiography.
CONCLUSIONS Nonsurgical septal reduction therapy resulted in a significantly higher incidence of complete
heart block, but the risk was reduced with contrast echocardiography and slow ethanol
injection. Surgical myectomy resulted in a significantly higher incidence of mild aortic
regurgitation. Nonsurgical septal reduction therapy, guided by contrast echocardiography, is
an effective procedure for treating patients with HOCM. The hemodynamic and functional
improvements at one year are similar to those of surgical myectomy. (J Am Coll Cardiol
2001;38:1701–6) © 2001 by the American College of Cardiology
Surgical septal myectomy is the standard treatment for
patients with hypertrophic obstructive cardiomyopathy
(HOCM) who are refractory to medical therapy. Successful
septal myectomy relieves symptoms and improves exercise
tolerance in the great majority of these patients. Further-
more, the treatment’s effects are usually sustained and, when
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performed in experienced centers, it is a safe procedure with
low morbidity and mortality (1–6). Nonetheless, early
results from several centers in Europe and the U.S. (7–10)
suggest that nonsurgical septal reduction therapy (NSRT) is
a similarly effective therapy. We sought to compare the
hemodynamic efficacy, at one year, of both treatment
modalities in two groups of patients matched for both age
and left ventricular outflow tract (LVOT) gradient.
METHODS
The first 41 consecutive HOCM patients at Baylor College
of Medicine with a resting dynamic LVOT gradient
40 mm Hg who underwent NSRT were compared to 41
septal myectomy patients at the Mayo Clinic, matched for
age and LVOT gradient. The presence of only a provokable
gradient (n  40 in the NSRT group) was the only reason
for exclusion in this study. Also, no patients had to be
excluded because of loss of follow-up. The surgery patients
were identified from 148 patients with a resting gradient
40 mm Hg who underwent surgery during a similar time
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interval. All patients had asymmetric left ventricular hyper-
trophy with a septal thickness of at least 1.5 cm. Left
ventricular outflow tract obstruction was due to septal-
leaflet contact (from systolic anterior motion of the mitral
valve). Because of different techniques of provoking LVOT
obstruction at the two institutions, patients with only
provokable gradients were not enrolled in an attempt to
achieve similar and comparable samples. Likewise, those
with concomitant midventricular gradients, primary struc-
tural valvular abnormalities or anomalous insertion of the
papillary muscles were not included in this series. All
enrolled patients had been on beta-blocker agents, calcium
channel blockers and/or disopyramide, and remained symp-
tomatic.
Clinical and echocardiographic evaluation. Patients were
interviewed by experienced cardiologists who determined
their New York Heart Association (NYHA) classification,
Canadian Cardiovascular Society (CCS) angina class and
the presence of presyncope and/or syncopal episodes. Echo-
cardiographic studies were performed, as previously re-
ported (10), at baseline and one year. Observers who were
blinded to clinical data performed the echocardiographic
interpretation and, to ensure consistency, a random sample
of 20 postprocedure studies from each institution was
re-reviewed by two investigators (S. F. N., S. R. O.).
Measurements of septal thickness, maximum end-
diastolic (EDD) and end-systolic (ESD) dimensions and
left ventricular ejection fraction were performed according
to the recommendations of the American Society of Echo-
cardiography (11). Left ventricular outflow tract gradient
was measured with color-guided continuous-wave Doppler
of the outflow tract (12). Care was taken to avoid contam-
ination with the mitral regurgitation jet. The severity of
mitral and aortic regurgitation was assessed by color-Dopp-
ler techniques evaluating the size of the regurgitant jet to the
receiving chamber (13,14). All patients in the NSRT group
had follow-up data one year after NSRT. The mean
follow-up in the surgery group was 398  492 days.
Exercise protocols. Before and one year after NSRT, 25
patients who could exercise at baseline underwent stress
testing on a standard Bruce protocol. Previously validated
regression equations (15) were used to estimate the maximal
oxygen consumption (VO2 peak) and the metabolic equiva-
lents (METS). There were 23 patients in the myectomy
group who could exercise at baseline and therefore per-
formed symptom-limited maximal treadmill exercise testing
according to a standard Mayo Clinic protocol (16), with
simultaneous respiratory gas analysis. Standard algorithms
(adjusted for age, gender and activity level) were applied to
predict VO2 peak for each patient in both groups, and the
achieved value was then expressed as percent of the pre-
dicted value.
NSRT. Each patient provided informed consent before
NSRT, in accordance with a protocol approved by the
institutional review board of Baylor College of Medicine. In
patients without a pre-existing permanent pacemaker, tem-
porary pacing wires were placed according to standard
technique. Two-dimensional and Doppler echocardiogra-
phy were used throughout the NSRT procedure. A 2 
10 mm balloon catheter was introduced over a 0.014-in
standard wire into the septal perforator artery and inflated.
Subsequently, Omnipaque (Nycomed, Princeton, New Jer-
sey) was injected through the balloon lumen to delineate the
course of the septal branch and to ensure the lack of spillage
into the left anterior descending coronary artery. After the
first seven patients in this series, the procedure was modified
and contrast echocardiography was utilized (after Om-
nipaque injection, 1.5 ml Albunex [Mallinckrodt, St. Louis,
Missouri] diluted in an equal volume of saline). Depending
on the size of the vascular territory of the cannulated septal
branch, 2 ml to 5 ml of absolute ethanol were instilled
through the inflated balloon catheter and left in place for
5 min. This ethanol injection technique was modified after
the first 12 patients in this series such that ethanol was
injected slowly, at 1 ml/min. The electrocardiogram was
closely monitored for evidence of bradycardia and heart
block, and the ethanol injection was aborted upon the
development of high-grade atrioventricular block.
Angiography was repeated after balloon deflation both to
confirm the patency of the left anterior descending coronary
artery and occlusion of the target septal branch. If present,
other similarly sized vessels were injected whenever the
LVOT gradient (as determined by Doppler echocardiogra-
phy) was 16 mm Hg. After our experience in the first 100
cases, repeat injection of other amenable arteries was con-
sidered only in the presence of a residual gradient
30 mm Hg. This change was adopted because of further
gradient reduction following postintervention remodeling.
A 6F multipurpose catheter was used to measure the LVOT
gradient at baseline and after NSRT. Patients were observed
in the coronary care unit for 24 h and, in the absence of
high-degree atrioventricular block, the pacer wire was re-
moved. Patients were transferred to a telemetry unit for the
remainder of their hospital stay (total hospitalization aver-
aged three days).
Surgery. Standard cardiopulmonary bypass and myocardial
preservation techniques were used. After aortotomy, exci-
sion of the septum was initiated with two parallel longitu-
dinal incisions: one beneath the nadir of the right coronary
Abbreviations and Acronyms
ANOVA  analysis of variance
CCS  Canadian Cardiovascular Society
EDD  end-diastolic dimension
ESD  end-systolic dimension
HOCM  hypertrophic obstructive cardiomyopathy
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LVOT  left ventricular outflow tract
METS  metabolic equivalents
NSRT  nonsurgical septal reduction therapy
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cusp and the other beneath the commissure separating the
left and right cusps. The mass of myocardium extending to
the posteromedial papillary muscle was then excised. Addi-
tional muscle mass was excised toward the lateral attach-
ment of the anterior mitral leaflet. Before the aortotomy was
closed, the LVOT was inspected and palpated for complete-
ness of the resection.
Adequacy of myectomy was confirmed through measure-
ment of simultaneous left ventricular and aortic pressures
before and after cardiopulmonary bypass. Intraoperative
transesophageal echocardiography was utilized in all cases.
Statistics. We present baseline and follow-up values for
each of the two groups, with data expressed as mean 
standard deviation. For statistical analysis, the clinical,
hemodynamic and echocardiographic results of surgery and
NSRT were analyzed using a two-way repeated measures
analysis of variance (ANOVA). The factors considered were
time (baseline vs. follow-up) and the type of procedure
(surgery vs. NSRT). We report the p value for each main
effect. Further, we test whether the time data are dependent
on the procedure performed (interaction p value). Chi-
square or Fisher exact tests were applied to compare
categorical variables. Statistical significance was present
with a p  0.05.
RESULTS
There were 41 patients in each group; Table 1 shows their
baseline clinical characteristics. Twelve patients in the
surgery group and 11 in the NSRT group were at least 60
years old. The patient groups at baseline were similar except
for a higher prevalence of pre-existing dual-chamber pace-
makers in the surgery group (p  0.15). All patients were
severely limited by dyspnea or angina (at least class III), or
had recurrent, limiting presyncope/syncope. At the time of
the procedures, similar proportions of patients were receiv-
ing cardiovascular medications (Table 1). None of the
patients with NSRT in the present cohort had previous
cardiac surgery; likewise, none of the surgery patients had
undergone NSRT or any other surgical procedure (includ-
ing surgical procedures for HOCM).
Outcome after NSRT and surgery. HEMODYNAMICS.
Analysis using two-way repeated-measures ANOVA
showed that at one year, the LVOT gradient had decreased
significantly (baseline: 77  25 vs. follow-up: 6  10; p 
0.05). However, there was no significant difference with
respect to the type of procedure (NSRT: 42  19 vs.
surgery: 41  18.5; p  0.3). Analysis for interaction
revealed that the effect of time was not dependent on the
procedure (p  0.1). Therefore, the hemodynamic benefits
derived with NSRT and surgery were comparable.
SYMPTOMS. Improvements in NYHA and CCS angina
class were similar in both groups. All NSRT patients and 40
of 41 surgery patients were in NYHA class I or II one year
following the procedures. Likewise, there was a similar
reduction in presyncope/syncopal episodes after both NSRT
and surgery (Table 2). The improvement at follow-up was
not dependent on the type of procedure.
No significant differences were present in the use of
antiarrhythmics after either NSRT or surgery. Although
more patients in the surgery group were receiving beta-
blocker (p  0.001) and calcium channel antagonist (p 
0.029) therapy following surgery, 29 of 41 in this group
were receiving no cardiac medications or were on lower
doses postsurgery. Of note, postprocedural medical therapy
was institution-specific and not related to the reduction in
LVOT gradient.
Table 1. Baseline Characteristics of the NSRT and
Surgery Groups
NSRT
(n  41)
Surgery
(n  41)
Age (yrs) 49  17 49  16
LVOT gradient (mm Hg) 76  23 78  30
NYHA class
I and II 9 (22%)
II 4 (10%)
III and IV 37 (90%) 32 (78%)
Angina class
I 16 (39%) 16 (39%)
II 15 (37%) 10 (24%)
III 10 (24%) 15 (37%)
Presyncope 24/41 (59%)* 23/41 (56%)†
Permanent pacemaker‡ 9/41 (22%) 16/41 (39%)
Cardiac medications
Beta-blockers 31/41 (76%) 26/41 (63%)
Calcium antagonists 19/41 (46%) 18/41 (44%)
Disopyramide 8/41 (20%) 4/41 (10%)
Amiodarone 3/41 (7%) 4/41 (10%)
Sotalol 3/41 (7%) None
*18 with syncope. †6 with syncope. ‡In both groups, pacemakers were placed as
therapy for HOCM and not for heart block. There were no statistically significant
differences between the two groups (p  0.1).
HOCM  hypertrophic obstructive cardiomyopathy; LVOT  left ventricular
outflow tract; NSRT  nonseptal surgical reduction therapy; NYHA  New York
Heart Association.
Table 2. One-Year Results in the NSRT and Surgery Groups
NSRT
(n  41)
Surgery
(n  41)
LVOT gradient (mm Hg) 8  15 4  7
NYHA class
I 36 (88%) 32 (78%)
II 5 (12%) 8 (20%)
III 1 (2%)
Angina class
I 41 (100%) 38 (93%)
II 3 (7%)
Presyncope 2/41 (5%) 7/41 (17%)
Permanent pacemaker 18/41 (44%) 17/41 (41%)
Due to heart block 9/41 1/41*
Cardiac medications
Beta-blockers 7/41 (17%) 24/41 (59%)*
Calcium antagonists 1/41 (2%) 8/41 (20%)*
Disopyramide 3/41 (7%) 1/41 (2%)
Amiodarone None 3/41 (7%)
Sotalol 2/41 (4%) None
*p  0.05 vs. NSRT.
Abbreviations as in Table 1.
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EXERCISE TOLERANCE. Peak VO2 , METS and % of max-
imum predicted VO2 were similar at baseline in both NSRT
and surgical myectomy groups. These parameters and exer-
cise duration increased at one year in both groups (Table 3).
On analysis of the effect of time by two-way repeated-
measures ANOVA, the increase in VO2 peak (baseline:
19.6  5.3 vs. follow-up: 24  5.4, p  0.05), METS
(baseline: 5.6  1.6 vs. follow-up: 7  1.7, p  0.05) and
% of maximum VO2 peak (baseline: 56  13 vs. follow-up:
71  16, p  0.05) at one year were all significant. In the
analysis for the other main variable, the results of surgery
versus NSRT, however, were comparable for each parame-
ter (at VO2 peak, NSRT: 23.5  5.7 vs. surgery: 21  5.5;
METS, NSRT: 6.7  1.55 vs. surgery: 6  1.6; percent of
maximum VO2 peak, NSRT: 63.75 16.7 vs. surgery: 63
14; all p  0.3). At one-year postprocedure, the magnitude
of improvement in all parameters (exercise duration, VO2
peak and percent of maximum VO2 peak) was similar
irrespective of the intervention (interaction: p  0.2).
ECHOCARDIOGRAPHIC RESULTS. Analysis for the effect of
time by two-way repeated-measures ANOVA showed a
significant increase in left ventricular dimensions at
follow-up (EDD, baseline: 42.5  5.3 vs. follow-up:
45.75  5; ESD, baseline: 22  4.8 vs. follow-up: 26  5;
both p  0.05), along with a decrease in septal thickness
(baseline: 22.3  6.3 vs. follow-up: 12.5  4; p  0.05).
Analysis for the effect of NSRT versus surgery showed no
statistically significant difference between the two proce-
dures in the same parameters (EDD, NSRT: 44.6  5.1 vs.
surgery: 43.2  5.3; ESD, NSRT: 23  4.3 vs. surgery:
25.6  5.5; septal thickness, NSRT: 17.4  4.6 vs. surgery:
17.35  6.7; all p  0.3). Testing for interaction revealed
that the effect of time on echocardiographic measurements
did not depend on whether NSRT or surgery was the
therapeutic intervention (p  0.2). Left ventricular ejection
fraction was preserved after both procedures (Table 4).
Likewise, mitral regurgitation was significantly less after
these interventions, with a comparable improvement (p 
0.2).
COMPLICATIONS. One NSRT death occurred acutely in
the catheterization laboratory because of dissection of the
left anterior descending coronary artery while the vessel was
negotiated with a standard wire. There were no deaths in
the surgery group.
Nine patients underwent implantation of a permanent
pacemaker because of complete heart block after NSRT.
Seven of these implants occurred before we modified our
technique (i.e., contrast echocardiography and slow injec-
tion of ethanol). One surgical patient became pacemaker
dependent following the procedure. Overall, the incidence
of new complete heart block was higher in the NSRT group
(p  0.014 vs. surgery).
Implantable cardiac defibrillators (ICDs) were placed
because of ventricular dysrhythmias in four surgery patients
and one NSRT patient. One of the ICDs in the surgery
group was placed because of preoperative ventricular fibril-
lation, whereas the others were placed postoperatively as
primary prevention, based on risk factor profiles and not
necessarily clinical events. The NSRT patient received an
ICD for treatment of sustained ventricular tachycardia.
Eight of the 41 surgery patients (20%) developed transient
atrial fibrillation after surgery, but all were discharged in
Table 3. Exercise Tolerance in the NSRT and Surgery Groups
Pre-NSRT Post-NSRT Pre-Surgery Post-Surgery
Exercise duration (s) 289 (188–422) 417* (301–589) 330 (294–525) 480* (393–600)
Peak VO2 (ml/kg/min) 20.8  4.9 26.2  6.5* 18.9  5.7 22.2  5.3*
METS 5.9  1.4 7.5  1.9* 5.3  1.7 6.5  1.5*
% Maximal predicted VO2 55  15 72.5  18.4* 57  11.5 69  17*
*p  0.05 vs. baseline.
METS  metabolic equivalents; NSRT  nonsurgical septal reduction therapy; VO2  oxygen consumption.
Table 4. Echocardiographic Parameters in the NSRT and Surgery Groups
Pre-
NSRT
Post-
NSRT
Pre-
Surgery
Post-
Surgery
EDD (mm) 42.8  5 46.5  5.3* 41.5  5.5 45  4.8*
ESD (mm) 21  4.7 25  4* 23.4  5 27.8  6*
Ejection fraction (%) 73  9 70  12 73  14 68  7
Septal thickness (mm) 22.6  5.8 12.2  3.4* 22  7.3 12.7  6.1*
Mitral regurgitation (grade 0 to 4)
None 29 (71%) 19 (46%)
I 12 (29%) 20 (49%)
II 1 (5%)
I and II 36 (88) 34 (83%)
III 1 (5%)
III and IV 5 (12%) 7 (17%)
*p  0.01 vs. baseline
EDD  end-diastolic dimension; ESD  end-systolic dimension; NSRT  nonsurgical septal reduction therapy.
1704 Nagueh et al. JACC Vol. 38, No. 6, 2001
Surgery Versus NSRT for HOCM November 15, 2001:1701–6
normal sinus rhythm. There were no episodes of atrial
fibrillation post-NSRT.
None of the patients in either group developed worsening
mitral regurgitation. Aortic regurgitation of mild or mod-
erate severity occurred in 11 patients (27%) following
surgical myectomy (mild in 10 and moderate in 1; p 0.001
vs. before surgery). Post-NSRT, new aortic regurgitation of
mild severity was present in three patients (7%) (p  0.65
vs. pre-NSRT). The incidence of aortic regurgitation was
significantly higher after surgery (p  0.04 vs. NSRT).
There were no cerebrovascular accidents, ventricular sep-
tal defects or cardiac tamponade after either NSRT or
surgery.
DISCUSSION
Left ventricular outflow tract obstruction is present in 20%
to 30% of patients with HCM. A number of patients remain
symptomatic despite optimal medical therapy, and surgical
myectomy is usually recommended for these patients. My-
ectomy reduces or eliminates LVOT obstruction in most
individuals and its effects are usually sustained (1–6).
Sigwart noticed that inflating an angioplasty balloon cath-
eter in the septal perforator resulted in a significant decrease
in outflow obstruction (7). Subsequently, intracoronary
(septal perforator) ethanol injection gained popularity in
treating patients with HOCM who are refractory to medical
therapy. In this study, we compared NSRT with surgical
myectomy, the standard for treating refractory HOCM.
The study had 85% power to detect a difference of 20 
15 mm Hg between the two groups at an alpha level of 0.05.
Comparative performance of NSRT and surgery in elim-
inating LVOT obstruction. The two groups of patients
reported in this investigation had identical gradients at
baseline and achieved a similar hemodynamic improvement
after either procedure. This may be related to the similar
mechanisms for eliminating obstruction that both proce-
dures share. As noted in the previous text, a similar
reduction in basal septal thickness was noted after both
surgery and NSRT. We recently observed that the long-
term improvement in obstruction by NSRT is related to
widening in the LVOT and a reduction in the angle
between the mitral valve leaflets and the direction of blood
flow (17). These observations are similar to the mechanisms
by which successful surgery relieves LVOT obstruction
(18,19).
Effects of NSRT and surgery on symptoms and exercise
tolerance. The two patient groups had similar baseline
NYHA and CCS class. Also, a similar number in either
group suffered from presyncope and/or syncope at baseline.
After surgery 98% of the patients were in NYHA class I
or II, and after NSRT, 100% of the patients were in these
two classes. These results are well representative of the
previously reported (1–10) benefits achieved by both surgery
and NSRT. Although a placebo effect cannot be excluded,
this effect appears unlikely given the sustained improvement
in symptomatology as well as the corroboration provided by
exercise testing. Importantly, at baseline there were no
statistically significant differences between the two groups’
VO2 peak, METS or percentage achieved maximum pre-
dicted VO2; at follow-up both groups increased their exer-
cise tolerance to a similar extent. This improvement in
exercise parameters is likely related to improvement in
mitral regurgitation as well as to improvement in left
ventricular relaxation and stiffness (20,21).
Effects of NSRT and surgery on left ventricular size and
function. We observed an increase in left ventricular EDD
and ESD after both NSRT and surgery. The change was
similar in both groups and, importantly, the left ventricular
ejection fraction was preserved after both procedures. The
decrease in the severity of mitral regurgitation, as assessed
by color Doppler, is another important result of both
procedures. In patients with more severe mitral regurgita-
tion (grade III to IV), improvement of this valvular lesion
may have accounted for the lower left ventricular filling
pressures and the elimination of heart failure symptoms
after the successful relief of obstruction.
Complications of NSRT and surgery. One death oc-
curred acutely in the NSRT group. This resulted from a
guide-wire-induced dissection of the left anterior descend-
ing coronary artery. After this episode we modified our
approach and now use the high-torque floppy wire. As
expected, percutaneous interventions in older patients carry
more risk because of the presence of atherosclerotic lesions
that make their vessels more vulnerable to dissection. This is
also true for surgery, where mortality is higher in older
patients; however, no deaths were observed in the surgery
group.
Complete heart block necessitating permanent pacing
occurred in 22% of the NSRT group. Seven of the nine
cases of heart block occurred before modifying our tech-
nique as detailed above (see Methods and Results). Since
then, the incidence of heart block in a subsequent group of
160 patients has fallen to 8.6%. As previously reported, the
incidence of aortic regurgitation (albeit mild) and the
incidence of postoperative transient atrial fibrillation were
significantly higher after surgery. However, neither of these
has been previously associated with adverse long-term
morbidity or mortality. With NSRT, ventricular dysrhyth-
mias are also a potential risk following the induction of
infarction. Interestingly, in our study the use of ICDs was
comparable in both groups.
Study limitations. Our results may not be generalizable;
we compare the performance of two procedures at two
well-experienced centers. Also, this was not a randomized
trial and there may be differences in practice patterns
between the two institutions. However, our two groups were
well matched at baseline in several important variables,
including age, LVOT gradient, NYHA and CCS class, use
of cardiac medications and ventricular function.
Different exercise protocols were used at the two institu-
tions, rendering direct comparison of exercise times imprac-
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tical. Also, in the NSRT group, regression equations were
used to arrive at the peak VO2 and number of METS
achieved. Although there are some difficulties with the use
of these regression models, the equations adopted have been
previously well validated in a large population of 1,074
patients (15). Furthermore, the peak VO2 values in the
NSRT group were very similar to those of the surgery group
as well as those of other HOCM patients with a significant
degree of dyspnea, and corroborate the subjective NYHA
assessments.
Implications. For patients with HOCM who remain
symptomatic despite optimal medications, reduction of
LVOT obstruction by surgery or NSRT is beneficial.
NSRT and surgery appear to be equally effective in reducing
obstruction, and in improving symptoms and exercise tol-
erance. Also, in our patient cohort these benefits were
associated with a preserved ejection fraction. Although
initially the incidence of heart block was higher after NSRT,
the incidence of heart block after NSRT has been signifi-
cantly lower (8.6%) since we modified our technique.
Obviously, even in experienced centers both procedures
carry mortality and morbidity risks varying from minor
complications to death and, therefore, can only be justified
in the very select group of highly symptomatic HOCM
patients.
Although the long-term safety and efficacy of surgical
myectomy are known, and the effects of NSRT at one year
are similar to those of surgery, there is currently a paucity of
data to assess the outcome of NSRT beyond one year
(22,23). Our study both provides the base and exposes the
need for prospective randomized trials aimed at assessing
this nonmedical approach for the treatment of refractory
HOCM.
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